The Impact of Farnesoid X Receptor Activation on Intestinal Permeability in Inflammatory Bowel Disease
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The most important function of the intestinal mucosa is to form a barrier that separates luminal contents from the intestine. Defects in the intestinal epithelial barrier have been observed in several intestinal disorders such as inflammatory bowel disease (IBD). Recent studies have identified a number of factors that contribute to development of IBD including environmental triggers, genetic factors, immunoregulatory defects and microbial exposure. The current review focuses on the influence of the farnesoid X receptor (FXR) on the inhibition of intestinal inflammation in patients with IBD. The development and investigation of FXR agonists provide strong support for the regulatory role of FXR in mucosal innate immunity. Activation of FXR in the intestinal tract decreases the production of proinflammatory cytokines such as interleukin (IL) 1-beta, IL-2, IL-6, tumour necrosis factor-alpha and interferon-gamma, thus contributing to a reduction in inflammation and epithelial permeability. In addition, intestinal FXR activation induces the transcription of multiple genes involved in enteroprotection and the prevention of bacterial translocation in the intestinal tract. These data suggest that FXR agonists are potential candidates for exploration as a novel therapeutic strategy for IBD in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Intestinal barrier function: molecular regulation and disease pathogenesis
Groschwitz, K. R., & Hogan, S. P. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.05.038 · Cited by 1,775
Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor
Inagaki, T., Moschetta, A., Lee, Y.-K., Peng, L., Zhao, G., Downes, M., Yu, R. T., Shelton, J. M., Richardson, J. A., Repa, J. J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509592103 · Cited by 1,164 · cited 6×
“This enzyme participates in antibacterial defense by maintaining appropriate intestinal pH and ion balance, which is important for the homeostasis of intestinal luminal contents and epithelial barrier integrity (71).”
BackgroundInfluentialGadaleta, R. M., van Erpecum, K. J., Oldenburg, B., Willemsen, E. C. L., Renooij, W., Murzilli, S., Klomp, L. W. J., Siersema, P. D., Schipper, M. E. I., Danese, S., et al. (2011) · Gut · doi:10.1136/gut.2010.212159 · Cited by 870 · cited 4×
“It has been reported that FXR activation results in a decrease of epithelial permeability and proinflammatory cytokine messenger RNA expression in the murine intestinal mucosa (8).”
BackgroundResultInfluentialPellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743 · cited 3×
“Consistent with this, Gadaleta et al (8) also showed that administration of the FXR agonist INT-747 alleviated intestinal inflammation in two models of murine colitis.”
BackgroundThe bile acid receptor FXR is a modulator of intestinal innate immunity
Vavassori, P., Mencarelli, A., Renga, B., Distrutti, E., & Fiorucci, S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803978 · Cited by 655
Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response
Wang, Y.-D., Chen, W.-D., Wang, M., Yu, D., Forman, B. M., & Huang, W. (2008) · Hepatology · doi:10.1002/hep.22519 · Cited by 639 · cited 1×
“At the hepatic level, FXR is a negative modulator of NF-kB-mediated inflammation, reducing the expression of inflammatory mediators both in vivo and in vitro (69).”
BackgroundIntestinal barrier dysfunction in inflammatory bowel diseases
McGuckin, M. A., Eri, R., Simms, L. A., Florin, T. H. J., & Radford-Smith, G. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20539 · Cited by 627
Fos/AP‐1 proteins in bone and the immune system
Wagner, E. F., & Eferl, R. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00332.x · Cited by 537
Yang, F., Huang, X., Yi, T., Yen, Y., Moore, D. D., & Huang, W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1078 · Cited by 488 · cited 1×
“Interestingly, when these mice were followed-up for longer periods, hepatic levels of the proinflammatory cytokines IFN-g, TNF-a and IL-6 were increased, suggesting an additional immunoregulatory role for FXR (54).”
BackgroundFXR: a metabolic regulator and cell protector
Wang, Y.-D., Chen, W.-D., Moore, D. D., & Huang, W. (2008) · Cell Research · doi:10.1038/cr.2008.289 · Cited by 389 · cited 9×
“FXR is activated by bile salts and regulates the transcription of genes involved in bile salt synthesis, transport and metabolism in the liver and intestine, as well as genes involved in many different functions by binding FXR response elements (FXREs) in promoters of target genes as a heterodimer with the retinoid X…”
BackgroundInfluentialLorenzo-Zúñiga, V., Bartolí, R., Planas, R., Hofmann, A. F., Viñado, B., Hagey, L. R., Hernández, J. M., Mañé, J., Alvarez, M. A., Ausina, V., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50116 · Cited by 321
Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease
Nijmeijer, R. M., Gadaleta, R. M., van Mil, S. W. C., van Bodegraven, A. A., Crusius, J. B. A., Dijkstra, G., Hommes, D. W., de Jong, D. J., Stokkers, P. C. F., Verspaget, H. W., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023745 · Cited by 119 · cited 1×
“Nijmeijer et al (81) recently evaluated whether genetic variation in FXR is associated with IBD.”
Background
Cited by
Bile acid signaling in metabolic disease and drug therapy
Li, T., & Chiang, J. Y. L. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008201 · Cited by 935
“TGR5 and FXR agonists may have therapeutic benefit to Crohn’s disease patients (Lian et al., 2011; Pols et al., 2011b; Stojancevic et al., 2012; Stepanov et al., 2013).”
BackgroundGuts and Gall: Bile Acids in Regulation of Intestinal Epithelial Function in Health and Disease
Hegyi, P., Maléth, J., Walters, J. R., Hofmann, A. F., & Keely, S. J. (2018) · Physiological Reviews · doi:10.1152/physrev.00054.2017 · Cited by 269
Baars, A., Oosting, A., Knol, J., Garssen, J., & Van Bergenhenegouwen, J. (2015) · Microorganisms · doi:10.3390/microorganisms3040641 · Cited by 135
Bile acids activated receptors in inflammatory bowel disease
Biagioli, M., Marchianò, S., Carino, A., Di Giorgio, C., Santucci, L., Distrutti, E., & Fiorucci, S. (2021) · Cells · doi:10.3390/cells10061281 · Cited by 103
Metadata
- Authors
- Stojancevic, M., Stankov, K., & Mikov, M.
- Venue
- Canadian Journal of Gastroenterology
- Publisher
- Hindawi Limited
- Published
- 2012
- Volume
- 26
- Issue
- 9
- Pages
- 631-637
- ISSN
- 0835-7900 (ISSN-L)
- OpenAlex
- W1597214954
- Cited by
- 75
- References
- 14
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.